Amgen's Dazodalibep Shines in Sjögren's Disease Study, Multi-Billion-Dollar Potential
Amgen's investigational fusion protein, dazodalibep, has shown promise in treating Sjögren's disease. The Phase 3 OASIZ 301 study demonstrated that dazodalibep significantly reduced disease activity across various organs at 48 weeks. This improvement was seen as early as week four.
The trial enrolled approximately 621 patients with moderate-to-severe systemic disease activity and assessed secondary endpoints such as fatigue and tender and swollen joints. The safety profile of dazodalibep appeared favorable, with discontinuations due to adverse events occurring at a low rate and being similar across the treatment and placebo groups.
The analysts at Truist Securities stated that dazodalibep 'clears the first hurdle' in Sjögren's disease, shifting focus from Phase 3 efficacy risk toward commercial relevance. They predicted that this asset could become a multi-billion-dollar franchise due to meaningful market opportunity and concentrated competition in systemic disease.
However, the analysts cautioned that the data readout was limited and that full Phase 3 data is needed 'to establish the quality of the win.' Amgen plans to present detailed findings from OASIZ 301 at an upcoming medical congress.